Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a platform designed to rebalance the body’s immune system and restore homeostasis. Through its developmental Advanced Immunomodulating Multi-Component System (AIMS) platform, it has advanced several late-stage developmental product candidates that include the STAT-200 and STAT-600 AIMS programs that are evaluating noroxymorphone and proenkephalin analogs for the treatment of certain cancer, inflammatory, autoimmune, and emerging viruses. Its STAT-201is focused on the restoration of mucosal healing and intestinal barrier function as an adjunct to the standard of care in moderate to severe Crohn’s Disease. Its STAT-205 is to potentially treat acute and post-acute COVID infections by modulating immune system function and by decreasing elevated inflammatory responses associated with SARS-CoV-2 viral infections.